European Journal of Haematology

Papers
(The median citation count of European Journal of Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome106
The hematologic consequences of obesity89
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis64
The incidence, complications, and treatment of iron deficiency in pregnancy44
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia40
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies39
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus36
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series36
Anticoagulation strategies in extracorporeal circulatory devices in adult populations32
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice31
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies27
Current understanding and future implications of sepsis‐induced thrombocytopenia27
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re27
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab26
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers26
Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent25
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors24
The role of ROTEM variables based on clot elasticity and platelet component in predicting bleeding risk in thrombocytopenic critically ill neonates24
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 201923
Long‐term follow‐up of patients with venous thromboembolism and COVID‐19: Analysis of risk factors for death and major bleeding23
Iron chelation therapy22
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA22
Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant21
Comorbidities in multiple myeloma and implications on survival: A population‐based study21
Comorbidities and complications in adults with pyruvate kinase deficiency21
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma20
Validation of the HScore and the HLH‐2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort20
The role of oral iron in the treatment of adults with iron deficiency20
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)19
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia19
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression18
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world17
Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies17
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment17
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement17
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and qual16
T cell–mediated autoimmunity in immune thrombocytopenia16
Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review15
Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation15
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS15
Acquired aplastic anemia following SARS‐CoV‐2 vaccination14
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?14
Real‐world data on voxelotor to treat patients with sickle cell disease14
Treatment horizon in multiple myeloma14
Assessing the risk of thromboembolism in cancer patients receiving immunotherapy14
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells14
Recombinant factor VIII Fc for the treatment of haemophilia A13
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study13
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group13
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti13
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?13
Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant13
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement13
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review12
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy12
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f12
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data12
Role of pre‐transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML12
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation11
Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma11
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution11
Next‐generation sequencing in hypoplastic bone marrow failure: What difference does it make?11
Haploidentical transplantation in pediatric non‐malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)11
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries11
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL11
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort11
Molecular pharmacology in complement‐mediated hemolytic disorders11
Principles of care for acquired hemophilia11
Image‐guided core needle biopsy as the first‐line diagnostic approach in lymphoproliferative disorders—A review of the current literature11
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes11
CAR‐T cell therapy for patients with hematological malignancies. A systematic review10
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real‐World Experience from 554 sequential core biopsies from a single centre10
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis10
Late occurrence of progressive multifocal leukoencephalopathy after anti‐CD19 chimeric antigen receptor T‐cell therapy10
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study10
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation10
The hemostatic and thrombotic complications of liver disease10
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis10
Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T‐cell therapy9
Survival trends in elderly myeloma patients9
POEMS syndrome: A multisystem clonal disorder9
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders9
Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies9
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?9
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies9
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia9
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders9
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts9
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia9
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma9
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics8
Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study8
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies8
Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children8
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination8
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia8
Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms8
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes8
mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis8
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance8
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐depe8
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series7
Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation7
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up7
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy7
Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary7
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis7
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome7
Incidence of adult primary immune thrombocytopenia in England—An update7
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey7
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)7
Bleeding complications in bcrabl‐negative myeloproliferative neoplasms (MPN): A retrospective single‐center study of 829 MPN patients7
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease7
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self‐ISTH‐BAT)7
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma7
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)7
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow‐up7
“Ex‐vivo” T‐cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges7
Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review7
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era7
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort7
Systematic review of hematuria and acute renal failure with tranexamic acid7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents7
IKZF1plus alterations are not associated with outcomes in Philadelphia‐positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD26
Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees6
Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation6
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol6
A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A6
Standardization for obtaining blood viscosity: A systematic review6
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions6
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review6
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia6
Congenital erythrocytosis6
Chimeric antigen receptor T cells for acute myeloid leukemia6
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients6
Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: Effects of hydroxyurea treatment and impact of sickle cell syndrome6
Artificial intelligence in the prediction of venous thromboembolism: A systematic review and pooled analysis6
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome6
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases6
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera6
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA6
A retrospective study of treosulfan versus busulfan‐based conditioning in pediatric patients6
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review6
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study6
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody6
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia6
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease6
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML6
Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma6
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma6
Clinical utility of targeted next‐generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: A national reference laboratory experience6
Outcomes after intensive care unit admission in newly diagnosed diffuse large B‐cell lymphoma patients: A real‐life study5
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)5
Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals5
Teclistamab‐cqyv in multiple myeloma5
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute5
Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation5
Transfusion requirements in patients with COVID‐195
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study5
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma5
Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data5
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors5
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma5
A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands5
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy5
Clinical and microbiological impact of long‐term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia5
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes5
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trial5
VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma5
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation5
The evolution of immune dysfunction in multiple myeloma5
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon5
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival5
High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia‐negative myeloproliferative neoplasms5
Patterns of previous and secondary malignancies in patients with multiple myeloma5
Post‐transplantation erythrocytosis in kidney transplant recipients—A retrospective cohort study5
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma5
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation5
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions5
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial5
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma5
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte5
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada5
Characterization and prognostic implication of delayed complete response in AL amyloidosis4
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study4
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le4
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg4
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients4
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia4
Markers of neutrophil chemotaxis for identification of blood stream infections in children with acute lymphoblastic leukemia undergoing induction treatment4
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management4
Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non‐Hodgkin lymphoma4
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management4
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK4
Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle4
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis4
The impact of changed treatment patterns in multiple myeloma on health‐care utilisation and costs, myeloma complications, and survival: A population‐based comparison between two time periods in Denmar4
Radiation‐free myeloablative conditioning consisting of fludarabine added to full‐dose busulfan and cyclophosphamide in single‐unit cord blood transplantation for adults4
Assessment of agreement between EXTEM and NATEM thromboelastometry measurement assays in critically ill neonates4
Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma4
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France4
Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia4
Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis4
Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?4
Anakinra versus etoposide‐based therapy added to high‐dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis4
Long‐term survivorship care after CAR‐T cell therapy4
Clinical, biological, and outcome features of P2RY8‐CRLF2 and CRLF2 over‐expression in pediatric B‐cell precursor acute lymphoblastic leukemia according to the 4
Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting4
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?4
Extended treatment response to imatinib in Rosai‐Dorfman disease4
Luspatercept, a two‐edged sword in beta‐thalassemia‐associated paravertebral extramedullary hematopoietic masses (EHMs)4
4
Screening of the protein C pathway abnormality‐related thrombophilia by using thrombomodulin‐mediated tissue factor‐triggered clot waveform analysis4
Vitamin E and acute graft‐versus‐host disease after myeloablative allogeneic hematopoietic cell transplantation4
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study4
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine4
Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors4
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept4
Prevalence and outcomes of pulmonary embolism with sickle cell disease: Analysis of the Nationwide Inpatient Sample, 2016–20204
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol4
Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia‐chromosome negative myeloproliferative neoplasms4
Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias4
Long‐term effectiveness of eculizumab: Data from the International PNH Registry4
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study4
A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia4
The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands4
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic4
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience4
Ex vivo T‐cell depletion vs post‐transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft‐vs‐host disease prophylaxis for allogeneic hematopoietic stem cell transplantation4
A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia4
Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility4
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study4
Upregulation of microRNA‐597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition4
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies4
Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications4
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study4
Impact of secondary‐type mutations in NPM1 mutated AML4
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity3
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis3
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma3
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology3
Bone metabolism parameters and their relation to cytogenetics in multiple myeloma3
The ektacytometric elongation Index (EI) of erythrocytes, validation of a prognostic, rheological biomarker for patients with sickle cell disease3
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study3
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal He3
Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis3
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes3
Treatment and prognosis of primary pulmonary lymphoma: A long‐term follow‐up study3
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial3
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care3
0.096220016479492